A Phase 3 interventional study of 0.3% OPA-15406 ointment and 1% OPA-15406 ointment in Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.
Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 2nd largest by enrollment, is one of 3 that started in 2019, is one of 10 in phase 3, and was the 9th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 15–70
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 3 mo–14 yrs
By country, each count listing its studies:
difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2019.
This study's enrollment of 366 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 177 across the 16 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
13 studies in Dermatitis, Atopic by Otsuka Holdings Co., Ltd.: 2 open now, 2 under way, 2 of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 13 studies in Dermatitis, Atopic by Otsuka Holdings Co., Ltd., this one has the largest enrollment, is one of 3 that started in 2019, is one of 8 in phase 3, and was the 8th registered.
Otsuka Holdings Co., Ltd.’s Dermatitis, Atopic studies by the year they started, since 2012.
2 of the studies testing difamilast in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173478Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | 2026-12 |
| NCT07184645Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing difamilast in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 13 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate the safety of 1% OPA-15406 ointment in adult patients with AD and of 0.3% and 1% OPA-15406 ointments in pediatric patients with AD administered twice daily for 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Twice daily
Drug: 0.3% OPA-15406 ointment
Twice daily
Drug: 1% OPA-15406 ointment
Twice daily
Twice daily
Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs)
The number of subjects were calculated regarding adverse events occurring after IMP administration (=TEAEs).
Time frame: Treatment period (52 weeks)
Responder Rate of Investigator's Global Assessment (IGA)
The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 52. Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.
Time frame: Week 52
Responder Rate of Eczema Area and Severity Index 75 (EASI 75)
The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD. The investigator or sub investigator scored the severity (0-3 points) and affected body surface area (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs). EASI 75 is defined as the rate of subjects whose EASI score has improved at least 75% from baseline.
Time frame: Week 52
| Milestone | Adult: 1% OPA-15406 Ointment | Pediatric: 0.3% OPA-15406 Ointment | Pediatric: 1% OPA-15406 Ointment |
|---|---|---|---|
| Started | 166 | 144 | 56 |
| Completed | 124 | 127 | 51 |
| Not completed | 42 | 17 | 5 |
| Withdrew: Adverse event | 13 | 5 | 2 |
| Withdrew: Withdrawal by subject | 17 | 2 | 1 |
| Withdrew: Withdrawal by parent/guardian | 0 | 7 | 0 |
| Withdrew: Physician decision | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 1 |
| Withdrew: Other | 6 | 1 | 0 |
The number of subjects were calculated regarding adverse events occurring after IMP administration (=TEAEs).
| Participants | Adult: 1% OPA-15406 Ointment | Pediatric: 0.3% OPA-15406 Ointment | Pediatric: 1% OPA-15406 Ointment |
|---|---|---|---|
| Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) | 120 | 131 | 47 |
The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 52. Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.
| percentage of participants | Adult: 1% OPA-15406 Ointment | Pediatric: 0.3% OPA-15406 Ointment | Pediatric: 1% OPA-15406 Ointment |
|---|---|---|---|
| Responder Rate of Investigator's Global Assessment (IGA) | 34.94 (27.71 to 42.71) | 52.78 (44.29 to 61.15) | 51.79 (38.03 to 65.34) |
The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD. The investigator or sub investigator scored the severity (0-3 points) and affected body surface area (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs). EASI 75 is defined as the rate of subjects whose EASI score has improved at least 75% from baseline.
| percentage of participants | Adult: 1% OPA-15406 Ointment | Pediatric: 0.3% OPA-15406 Ointment | Pediatric: 1% OPA-15406 Ointment |
|---|---|---|---|
| Responder Rate of Eczema Area and Severity Index 75 (EASI 75) | 55.42 (47.52 to 63.13) | 77.08 (69.35 to 83.67) | 64.29 (50.36 to 76.64) |
Collected over Treatment period (52 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adult: 1% OPA-15406 Ointment | 0/166 (0%) | 2/166 (1.2%) | 72/166 (43.4%) |
| Pediatric: 0.3% OPA-15406 Ointment | 0/144 (0%) | 1/144 (0.7%) | 108/144 (75%) |
| Pediatric: 1% OPA-15406 Ointment | 0/56 (0%) | 0/56 (0%) | 43/56 (76.8%) |
| Event | Adult: 1% OPA-15406 Ointment | Pediatric: 0.3% OPA-15406 Ointment | Pediatric: 1% OPA-15406 Ointment |
|---|---|---|---|
| Pneumonia bacterialInfections and infestations | 0/166 | 1/144 | 0/56 |
| Rhegmatogenous retinal detachmentEye disorders | 1/166 | 0/144 | 0/56 |
| Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/166 | 0/144 | 0/56 |
| Event | Adult: 1% OPA-15406 Ointment | Pediatric: 0.3% OPA-15406 Ointment | Pediatric: 1% OPA-15406 Ointment |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 24/166 | 47/144 | 17/56 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 35/166 | 30/144 | 17/56 |
| ImpetigoInfections and infestations | 2/166 | 26/144 | 5/56 |
| InfluenzaInfections and infestations | 5/166 | 21/144 | 4/56 |
| Conjunctivitis allergicEye disorders | 5/166 | 14/144 | 7/56 |
| GastroenteritisInfections and infestations | 5/166 | 11/144 | 6/56 |
| UrticariaSkin and subcutaneous tissue disorders | 8/166 | 14/144 | 3/56 |
| FolliculitisInfections and infestations | 10/166 | 9/144 | 5/56 |
| PharyngitisInfections and infestations | 0/166 | 6/144 | 4/56 |
| BronchitisInfections and infestations | 1/166 | 9/144 | 3/56 |
Safety set: subjects who have received the investigational medicinal product (IMP) at least once
| Age, Continuous(years) | Adult: 1% OPA-15406 Ointment | Pediatric: 0.3% OPA-15406 Ointment | Pediatric: 1% OPA-15406 Ointment | Total |
|---|---|---|---|---|
| Mean | 33.7 ± 11.3 | 7.1 ± 3.5 | 8.3 ± 3.5 | 7.4 ± 3.5 |
| Sex: Female, Male(Participants) | Adult: 1% OPA-15406 Ointment | Pediatric: 0.3% OPA-15406 Ointment | Pediatric: 1% OPA-15406 Ointment | Total |
|---|---|---|---|---|
| Female | 65 | 63 | 18 | 146 |
| Male | 101 | 81 | 38 | 220 |
| Race/Ethnicity, Customized(Participants) | Adult: 1% OPA-15406 Ointment | Pediatric: 0.3% OPA-15406 Ointment | Pediatric: 1% OPA-15406 Ointment | Total |
|---|---|---|---|---|
| Asian | 166 | 144 | 56 | 366 |
| Region of Enrollment(Participants) | Adult: 1% OPA-15406 Ointment | Pediatric: 0.3% OPA-15406 Ointment | Pediatric: 1% OPA-15406 Ointment | Total |
|---|---|---|---|---|
| Japan | 166 | 144 | 56 | 366 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Ran from May 2019 to primary completion in Nov 2020, 17 months.
Results were first posted in Nov 2021, 1 year after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 17 months is close to that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Difamilast
Otsuka Pharmaceutical Co., Ltd. →